September 30, 2014
Mucosis B.V., a clinical stage biotechnology company developing novel vaccines for infectious diseases, will present updates on its research and development program at the Biotech in Europe Forum taking place in Basel, Switzerland 30 September through 01 October 2014.
Mucosis, which has recently announced several strategic partnerships including one with the Netherlands Enterprise Agency, an agency of the Dutch Ministry of Economic Affairs, and another with China-based Changchun BCHT Biotechnology Co (BCHT), is advancing its lead product, SynGEM®, as a vaccine candidate for Respiratory Syncytial Virus (RSV).
“It’s an exciting time to be involved in novel vaccine development, given the urgent public health need to prevent infectious diseases in all corners of the world,” said Thomas Johnston, chief executive officer, Mucosis. “Based on our clinical-stage proprietary Mimopath® platform, Mucosis is well-positioned to deliver vaccines that can provide the first line of defense against infectious disease pathogens. We are pleased to have the opportunity to share updates on our pipeline with the investment community and also meet with potential partners at this meeting.”
Mr. Johnston will be presenting at 16:05 on September 30, and his presentation can be viewed on the Mucosis website www.mucosis.com from October 1, 2014.
Mr. Johnston will also be speaking on a panel discussion on vaccines, alongside representatives from Sanofi Pasteur MSD, Philimmune, Genocea Biosciences, VBI Vaccines, ABIVAX, Biomay, and Sofinnova Partners.
– ENDS –
Note for Editors
Mucosis B.V. is a clinical-stage biotechnology company developing novel vaccines on its proprietary Mimopath® platform technology. The Mimopath® platform is being studied for various routes of administration including those that provide additional protection in the mucosa, the site where over 90% of pathogens enter the human body. Mucosis’s lead product SynGEM®, a stabilized prefusion F protein recombinant vaccine to prevent RSV infection in various target groups, is poised to enter human proof-of-concept studies. The company has also developed PneuGEM®, a vaccine to prevent diseases caused by pneumococcal bacteria and FluGEM®, a vaccine to prevent influenza which served as a successful Mimopath® platform proof of concept through human clinical testing. Mucosis is based in The Netherlands.
About Mimopath® technology
The Mimopath® technology is based on Lactococcus lactis, a Generally Recognized As Safe (GRAS) bacterium commonly used in the food industry. Mucosis has developed a robust proprietary technique to formulate the L. lactis bacteria into non-living bacterium-like particles (BLPs) that can be covered with antigens from viral, bacterial, parasitic or tumor origin. BLP-based vaccines are particularly suitable to administer into the nose or mouth, without a needle. Mucosal vaccines have been shown to raise protective immunity by activation of both the innate and the adaptive immune system.
SynGEM®, Mucosis’s lead vaccine candidate currently completing preclinical studies, is being developed in cooperation with corporate, governmental and non-governmental partners across the globe. SynGEM® is designed to prevent infections with RSV, which affect over 60 million people worldwide and are responsible for more than one million hospitalizations and 160,000 deaths annually. The proprietary RSV prefusion F protein in SynGEM® displays valuable epitopes considered to be important for optimal virus neutralization and is suitable for use in different formulations and administration routes to efficiently address various target groups. There are currently no available vaccines for RSV.
Issued for and on behalf of Mucosis by Instinctif Partners.
For more information please visit www.mucosis.com.